{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cramer-van der Welle CM"],"funding":["KWF Kankerbestrijding"],"pagination":["6306"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7973789"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer (NSCLC) in 2015-2018 in six Dutch large teaching hospitals (Santeon network) were identified and followed-up from date of diagnosis until death or end of data collection. Progression-free survival (PFS) and overall survival (OS) from first-line (1L) pembrolizumab and second-line (2L) nivolumab were compared with clinical trial data by calculating hazard ratios (HRs). From 1950 diagnosed patients, 1005 (52%) started with any 1L treatment, of which 83 received pembrolizumab. Nivolumab was started as 2L tr"],"journal":["Scientific reports"],"pubmed_title":["Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands."],"pmcid":["PMC7973789"],"funding_grant_id":["SAN2016-7942"],"pubmed_authors":["van den Borne BEEM","Cramer-van der Welle CM","Smit AAJ","Schramel FMNH","Santeon NSCLC Study Group","Kastelijn EA","Tonn M","Peters BJM","Groen HJM","van de Garde EMW","Schouwink JH","Klungel OH","Vermeer LC","Verschueren MV","van Putten JWG"],"additional_accession":[]},"is_claimable":false,"name":"Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.","description":"This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap. All patients diagnosed with stage IV non-small cell lung cancer (NSCLC) in 2015-2018 in six Dutch large teaching hospitals (Santeon network) were identified and followed-up from date of diagnosis until death or end of data collection. Progression-free survival (PFS) and overall survival (OS) from first-line (1L) pembrolizumab and second-line (2L) nivolumab were compared with clinical trial data by calculating hazard ratios (HRs). From 1950 diagnosed patients, 1005 (52%) started with any 1L treatment, of which 83 received pembrolizumab. Nivolumab was started as 2L tr","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-22T17:55:27.447Z","creation":"2025-04-06T02:14:00.984Z"},"accession":"S-EPMC7973789","cross_references":{"pubmed":["33737641"],"doi":["10.1038/s41598-021-85696-3"]}}